Antibodies
7 November 2012
The Lancet Publication Of LAPLACE-TIMI 57 And MENDEL Studies Showed AMG 145 Significantly Reduced LDL Cholesterol7 November 2012
FDA grants Roche’s trastuzumab emtansine (T-DM1) Priority Review for HER2-positive metastatic breast cancer6 November 2012
Clearside Biomedical Announces First Successful Human Dosing in a Safety and Tolerability Study in Patients with Retinal Disease5 November 2012
New Clinical Trial Data Show Substantial Improvement with Eculizumab (Soliris) in Patients with STEC-HUS5 November 2012
Two-Year Data Show Long-Term Benefits of Chronic Soliris Therapy in Patients with aHUS5 November 2012
Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia5 November 2012
MorphoSys Announces Presentation of Preclinical Data on MOR202 and MOR208 at 2012 American Society of Hematology Annual Meeting5 November 2012
GSK announces FDA Advisory Committee vote in favour of raxibacumab for the treatment of inhalational anthrax infection1 November 2012
Millennium and Seattle Genetics Initiate Global Phase 3 Clinical Trial of ADCETRIS in Previously Untreated Advanced Hodgkin Lymphoma1 November 2012
Roche medicine Avastin receives EU approval for the treatment of women with recurrent, platinum-sensitive ovarian cancer31 October 2012
Millennium and Takeda Announce European Conditional Marketing Authorization for ADCETRIS (Brentuximab Vedotin)29 October 2012
GSK announces start of Phase lll programme for mepolizumab in severe refractory asthma29 October 2012
Visterra presents prophylactic and therapeutic efficacy data of VIS410 against the H5N1 (Avian Flu) influenza strain in Hanoi, Viet Nam29 October 2012
XBiotech Reports Positive Phase II Interim Analysis Results From Type 2 Diabetes Study26 October 2012
Theraclone Sciences Initiates Phase 2 Viral Challenge Clinical Study of Therapeutic Antibody for the Treatment of Influenza A25 October 2012
Biotest AG expands existing product portfolio with the marketing authorisation of Intratect 100 g/l (10%)24 October 2012
Fujifilm Diosynth Biotechnologies Announces Strategic Alliance with Piramal Healthcare for Production of Antibody Drug Conjugates18 October 2012
Crohn’s Disease Patients Refractory To Tumor Necrosis Factor Inhibitors Showed Improvement In Disease With STELARA Treatment17 October 2012
Seattle Genetics Announces Initiation of Phase II Trial of ADCETRIS as Front-line Therapy for Hodgkin Lymphoma Patients Age 60 and OverNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports